FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a group of specific compounds specified in the claims, or their pharmaceutically acceptable salts. Also provided are a compound of formula IId or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, the use of the compounds, and a method for irreversible inhibition of Bruton’s tyrosine kinase.
EFFECT: proposed compounds are effective as inhibitors of the Bruton’s tyrosine kinase and can be used to treat cancer, chronic inflammation and an autoimmune disease that are mediated, at least partially, by Bruton's tyrosine kinase.
10 cl, 4 tbl, 73 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | 2013 |
|
RU2652117C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| PYRIDAZINE DERIVATIVE INHIBITOR, METHOD OF ITS PREPARATION AND ITS USE | 2020 |
|
RU2807611C2 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION | 2018 |
|
RU2765785C2 |
| PHENOXYPYRIDINYLAMIDE DERIVATIVES, AND THEIR USE IN TREATMENT OF PDE4-MEDIATED DISEASE STATES | 2009 |
|
RU2509077C2 |
| NEW COMPOUNDS FOR TREATING AMYLOID OR AMYLOID-LIKE PROTEIN ASSOCIATED DISEASES | 2007 |
|
RU2469026C2 |
| HETEROCYCLIC COMPOUNDS FOR TYROSINE KINASE 2 ACTIVITY MEDIATION | 2020 |
|
RU2826012C2 |
